Center on Health Equity & Access

Discussion covered lung cancer biomarker testing, care in hematologic malignancies, health equity in cancer screening, and medically integrated pharmacy dispensing

988 Lifeline rollout linked to 11% drop in youth suicide deaths, with greater reductions in states with higher call uptake, study finds.

There was comparable 12-month fitness and functional outcomes in lymphoma survivors, suggesting a scalable option to expand access to cardio-oncology care.

Young-onset CRC mortality rose over 3 decades in the US, largely among adults with lower educational attainment, widening socioeconomic gaps.

Black Maternal Health Week spotlights disparities, Medicaid postpartum coverage gains, and ongoing policy efforts to reduce maternal mortality.

Clinical trials are evolving toward decentralized, patient-centered models, but enrollment challenges, outdated protocols, and infrastructure gaps persist.

Results of 2 programs show what it takes to move social determinants of health from research into clinical practice—and what’s still missing.

Food insecurity remains among children above SNAP limits, highlighting broad-based categorical eligibility gaps that exclude at-risk families just over eligibility thresholds.

Receipt of an insurer-provided grocery benefit was associated with decreased rates of diabetes with complications and increased medication adherence among a population with diabetes.

Daryl Pritchard, PhD, discusses the challenges to implementing biomarker testing that would advance precision medicine and improve patient outcomes in oncology.

At AMCP 2026, Kelsea Aragon, PharmD, discussed PrEP coverage, long-acting injectables, and payer strategies to improve HIV treatment access and adherence.

Quality metrics for screening tests must evolve to mandate diagnostic resolution, ensuring financial and clinical incentives prioritize the complete screening continuum over initial test uptake.

At AMCP 2026, Adam Colborn, JD, warns the Alternatives to PAIN Act may expand access but risk destabilizing Medicare Part D and limiting plan participation.

Abby Kim, PharmD, delves into oncology trends, biomarker testing gaps, and evolving clinical pathways shaping precision care and treatment decisions.

The 2026 Regional Diabetes Summit is taking place from April 28 to 29, 2026, in Wilmington, Delaware.

Ben Urick, PharmD, PhD, examines GLP-1 coverage gaps and real-world evidence challenges shaping payer decisions and obesity treatment access.

Hayley Knollman, MD, explains how ctDNA and genomic testing impact ER-positive metastatic breast cancer care, guiding sequencing decisions amid evolving HER2 categories.

High co-payments for potentially curative cell and gene therapies create avoidable access barriers; value-based insurance design should eliminate patient cost sharing for these therapies.

At AMCP 2026, Daryl Pritchard, PhD, highlighted fragmentation, evidence gaps, and decision support needs limiting precision medicine adoption and outcomes.

Kelsea Aragon, PharmD, highlights the role of long-acting HIV therapies like lenacapavir and cabotegravir in improving adherence, flexibility, and prevention access.

Steven Kheloussi, PharmD, explains how care coordination and transparent policies can improve MS treatment adherence, streamline access, and balance costs.

Complex Medicaid patients randomly assigned to receive outpatient social worker care coordination services experienced increased hospitalizations but no differences in emergency department visits or costs.

Esketamine's monotherapy approval and new real-world data are forcing a reckoning for managed care.

A clinical pharmacy leader outlines 8 interdependent domains institutions must master to build financially sustainable, patient-accessible CGT programs.

Amy Leader, DrPH, MPH, explains that trust is key to clinical trial enrollment at an Institute for Value-Based Medicine event in Philadelphia.